PVLA Stock Analysis: Buy, Sell, or Hold?
PVLA - Palvella Therapeutics, Inc. Common Stock
$76.69
-5.21 (-6.36%)
▼
5d:
-10.09%
30d:
-23.22%
90d:
+2.02%
WAIT
LOW Confidence
Last Updated: January 30, 2026
Get Alerted When PVLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PVLA is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PVLA is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: PVLA is currently trading at $76.69, which is considered oversold relative to its 30-day fair value range of $86.04 to $103.09.
Technical Outlook: Technically, PVLA is in a strong uptrend. Immediate support is located at $72.22, while resistance sits at $104.14. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: PVLA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $184.07 (+140.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PVLA is in a strong uptrend. Immediate support is located at $72.22, while resistance sits at $104.14. Short-term momentum is weak, with the stock down 6.4% recently.
Market Sentiment: PVLA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (20th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $184.07 (+140.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$86.04 -
$103.09
Company Quality Score
51/100
(HOLD)
Options IV Signal
20th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
62.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 20th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.4%)
- BULLISH: Trading 140.0% below Wall St target ($184.07)
- WARNING: Recommendation downgraded due to -10.1% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$86.04 -
$103.09
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$9.19
(12.0%)
Support & Resistance Levels
Support Level
$72.23
Resistance Level
$104.14
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-18.96
Wall Street Target
$184.07
(+140.0%)
Last updated: February 02, 2026 7:57 AM ET
Data refreshes hourly during market hours. Next update: 8:57 AM
Data refreshes hourly during market hours. Next update: 8:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PVLA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
